Good news has been scarce for this beaten-down drugmaker.

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Pfizer has quietly built momentum in 2026 and Guggenheim just raised its price target to $36 while reiterating a Buy rating.

Up until recently, the stock has been a chronic underperformer.

Pfizer said its experimental Lyme disease vaccine was more than 70% efficacious in reducing confirmed cases of the tickborne ...

Pfizer is working to get approval on a new vaccine that could protect people against Lyme disease.

The vaccine could represent a weapon for preventing Lyme, a bacterial infection carried by ticks that is diagnosed and ...

Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true. However, dividends are paid out of cash flow, not earnings, so a payout ratio ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Pfizer has reached a turning point.

The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.

Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, a lackluster result ...